These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 34650610)

  • 21. Guidelines for pharmacotherapy in Alzheimer's disease - A primer on FDA-approved drugs.
    Varadharajan A; Davis AD; Ghosh A; Jagtap T; Xavier A; Menon AJ; Roy D; Gandhi S; Gregor T
    J Neurosci Rural Pract; 2023; 14(4):566-573. PubMed ID: 38059250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delivery of Intravenously Administered Antibodies Targeting Alzheimer's Disease-Relevant Tau Species into the Brain Based on Receptor-Mediated Transcytosis.
    Tashima T
    Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer's Disease: Towards a Personalized Polypharmacology Patient-Centered Approach.
    Morató X; Pytel V; Jofresa S; Ruiz A; Boada M
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A tough trek in the development of an anti-amyloid therapy for Alzheimer's disease: Do we see hope in the distance?
    Luo JJ; Wallace W; Kusiak JW
    J Neurol Sci; 2022 Jul; 438():120294. PubMed ID: 35635864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer's Disease.
    Krafft GA; Jerecic J; Siemers E; Cline EN
    Front Neurosci; 2022; 16():848215. PubMed ID: 35557606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.
    Tolar M; Abushakra S; Hey JA; Porsteinsson A; Sabbagh M
    Alzheimers Res Ther; 2020 Aug; 12(1):95. PubMed ID: 32787971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Editorial: Targets for Disease-Modifying Therapies in Alzheimer's Disease, Including Amyloid β and Tau Protein.
    Parums DV
    Med Sci Monit; 2021 Jul; 27():e934077. PubMed ID: 34305135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aducanumab for Alzheimer's Disease: Summarized Data From EMERGE, ENGAGE, and PRIME Studies.
    Yuksel JM; Noviasky J; Britton S
    Sr Care Pharm; 2022 Aug; 37(8):329-334. PubMed ID: 35879846
    [No Abstract]   [Full Text] [Related]  

  • 30. Role of monomeric amyloid-β in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies.
    Imbimbo BP; Ippati S; Watling M; Imbimbo C
    Pharmacol Res; 2023 Jan; 187():106631. PubMed ID: 36586644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aducanumab: A look two years after its approval.
    Torres A; Camargo L; López N
    Biomedica; 2024 May; 44(Sp. 1):42-46. PubMed ID: 39079148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. "Aducanumab" making a comeback in Alzheimer's disease: An old wine in a new bottle.
    Behl T; Kaur I; Sehgal A; Singh S; Sharma N; Makeen HA; Albratty M; Alhazmi HA; Felemban SG; Alsubayiel AM; Bhatia S; Bungau S
    Biomed Pharmacother; 2022 Apr; 148():112746. PubMed ID: 35231697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aducanumab-Hope or Disappointment for Alzheimer's Disease.
    Wojtunik-Kulesza K; Rudkowska M; Orzeł-Sajdłowska A
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aducanumab: The first targeted Alzheimer's therapy.
    Yang P; Sun F
    Drug Discov Ther; 2021; 15(3):166-168. PubMed ID: 34234067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
    Pittock RR; Aakre JA; Castillo AM; Ramanan VK; Kremers WK; Jack CR; Vemuri P; Lowe VJ; Knopman DS; Petersen RC; Graff-Radford J; Vassilaki M
    Neurology; 2023 Nov; 101(19):e1837-e1849. PubMed ID: 37586881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Aducanumab and Alzheimer's disease: a critical reflection.].
    Vanacore N; Blasimme A; Canevelli M
    Recenti Prog Med; 2021; 112(7):495-498. PubMed ID: 34263875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease.
    Ferrero J; Williams L; Stella H; Leitermann K; Mikulskis A; O'Gorman J; Sevigny J
    Alzheimers Dement (N Y); 2016 Sep; 2(3):169-176. PubMed ID: 29067304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. From monomer to fibril: Abeta-amyloid binding to Aducanumab antibody studied by molecular dynamics simulation.
    Frost CV; Zacharias M
    Proteins; 2020 Dec; 88(12):1592-1606. PubMed ID: 32666627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Causal treatment of Alzheimer's disease: amyloid antibodies].
    Pawlowski M; Warnecke T
    Inn Med (Heidelb); 2022 Sep; 63(9):1000-1008. PubMed ID: 35290498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aducanumab: Appropriate Use Recommendations.
    Cummings J; Aisen P; Apostolova LG; Atri A; Salloway S; Weiner M
    J Prev Alzheimers Dis; 2021; 8(4):398-410. PubMed ID: 34585212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.